Methylprednisolone

證據等級: L5

預測適應症: 10 個

Methylprednisolone: From Corticosteroid Therapy to Alopecia Areata

One-Sentence Summary

Methylprednisolone is a systemic glucocorticoid; no specific original indication is recorded in this evidence pack, though it is broadly used for inflammatory and autoimmune conditions. The TxGNN model predicts it may be effective for Alopecia Areata, with 18 registered clinical trials retrieved (3 directly on methylprednisolone/pulse steroid therapy for alopecia areata, the rest are background noise from unrelated SLE/oncology trials) and 20 publications specifically on methylprednisolone pulse therapy in alopecia areata.

Quick Overview

Item	Content
Original Indication	Not specified in evidence pack (glucocorticoid, class-wide use for inflammatory/autoimmune/allergic disease)
Predicted New Indication	Alopecia Areata
TxGNN Prediction Score	99.99%
Evidence Level	L2
Taiwan Market Status	未上市 (Not Marketed)
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (Data Gap DG002), and no original indication is recorded for this candidate. Based on known pharmacology, methylprednisolone is a potent synthetic glucocorticoid used broadly for anti-inflammatory and immunosuppressive therapy across specialties.

Mechanistically, alopecia areata is an autoimmune disease driven by collapse of the hair follicle's immune-privileged status and infiltration of CD8+NKG2D+ T cells attacking the follicle. Methylprednisolone's immunosuppressive and anti-inflammatory action directly targets this pathway, which is consistent with its established dermatologic use: oral/IV pulse methylprednisolone is already a recognized clinical option for severe, treatment-resistant alopecia areata, supported by decades of case series and cohort data (see Literature Evidence below).

The prediction is therefore not a purely theoretical extrapolation — pulse corticosteroid therapy for alopecia areata is existing, real-world clinical practice, and the TxGNN score is corroborated by a directly relevant Phase 4 trial and a substantial, disease-specific literature base.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01167946	Phase 4	Completed	42	Oral mega-pulse methylprednisolone in severe, therapy-resistant alopecia areata; evaluates higher-dose, more frequent pulses than standard regimens
NCT07101471	N/A	Completed	296	Observational safety/effectiveness study of tofacitinib in alopecia, with participants receiving treatment with or without adjuvant prednisolone
NCT01017510	N/A	Unknown	20	Comparison of Dermojet vs. conventional syringe for intralesional steroid injection in alopecia areata

Note: The evidence pack's raw clinical trial search returned 18 records, but the majority (SLE trials of baricitinib/sirolimus/anifrolumab, a prostate cancer trial, a headache nerve-block trial) are keyword-matching noise unrelated to methylprednisolone in alopecia areata and have been excluded from this table.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
32270396	2020	Systematic Review	Dermatology and Therapy	Cyclosporine with/without systemic corticosteroids in alopecia areata treatment
37992355	2023	Review	Dermatology Practical & Conceptual	Efficacy and adverse effects of corticosteroid pulse therapy across AA severity
28378336	2017	Review	International Journal of Dermatology	Review of treatment options for alopecia totalis and universalis, including steroids
35986630	2022	Retrospective Cohort	Dermatologic Therapy	Methylprednisolone alone vs. methylprednisolone+methotrexate in extensive AA (n=26)
18608727	2008	Cohort	J Dermatological Treatment	Combination cyclosporine + methylprednisolone in severe AA
30745958	2019	Cohort	Open Access Maced J Med Sci	Methotrexate + mini-pulse methylprednisolone in severe AA (Vietnamese cohort)
25566921	2015	Cohort/Case Series	Indian J Dermatol Venereol Leprol	IV methylprednisolone pulse therapy in severe AA
36865845	2022	Retrospective/Review	Indian Journal of Dermatology	Sex differences in AA response to steroid pulse therapy
9777767	1998	Open Prospective Study	J American Academy of Dermatology	Pulse methylprednisolone in severe AA, open prospective study of 45 patients
21592197	2011	Cohort	The Journal of Dermatology	Prognostic factors for response to methylprednisolone pulse therapy (n=70)

New Zealand Market Information

Not applicable — the evidence pack reports 台灣 (Taiwan) regulatory status as 未上市 (not marketed), with 0 authorizations and no license records available. There is currently no TFDA-approved product listing for methylprednisolone to summarize in a market table.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: A Phase 4 trial and a consistent body of cohort/case-series literature (spanning 1993–2025) support oral/IV pulse methylprednisolone as an established off-label option for severe alopecia areata, corroborating the L2 evidence level. However, the drug is not currently marketed in Taiwan and two blocking/high-severity data gaps (TFDA package insert warnings/contraindications, and MOA data) remain unresolved.

To proceed, the following is needed:

TFDA package insert (warnings, contraindications) — currently a Blocking data gap (DG001) preventing S1 safety pre-assessment
Confirmed mechanism of action documentation from DrugBank (DG002)
Clarification of regulatory pathway, since methylprednisolone has no active Taiwan marketing authorization (0 licenses)
Drug-drug interaction data (current DDI query returned no results)
A dedicated dose/regimen protocol for pulse therapy in AA, since no completed randomized controlled trial specifically validates this use
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.